| 000 | 01387 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250514004544.0 | ||
| 264 | 0 | _c20020122 | |
| 008 | 200201s 0 0 eng d | ||
| 022 | _a0114-5916 | ||
| 024 | 7 |
_a10.2165/00002018-200124080-00003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLee, L M | |
| 245 | 0 | 0 |
_aTolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. _h[electronic resource] |
| 260 |
_bDrug safety _c2001 |
||
| 300 |
_a587-97 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnti-HIV Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntiretroviral Therapy, Highly Active _xadverse effects |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xetiology |
| 650 | 0 | 4 |
_aHIV Protease Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aHealth Personnel |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfectious Disease Transmission, Patient-to-Professional |
| 650 | 0 | 4 |
_aOccupational Exposure _xadverse effects |
| 650 | 0 | 4 | _aPatient Compliance |
| 650 | 0 | 4 | _aPregnancy |
| 650 | 0 | 4 |
_aReverse Transcriptase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aHenderson, D K | |
| 773 | 0 |
_tDrug safety _gvol. 24 _gno. 8 _gp. 587-97 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00002018-200124080-00003 _zAvailable from publisher's website |
| 999 |
_c11407589 _d11407589 |
||